XTLB (XTL Biopharmaceuticals) EBIT: $-6.61 Mil (TTM As of Jun. 2025)

What is XTL Biopharmaceuticals EBIT?

XTL Biopharmaceuticals XTLB -8.01% 24 EBIT is $-6.61 Mil as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

XTL Biopharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2025 was $-5.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was $-6.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. XTL Biopharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2025 was -144.95%. XTL Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -6,404.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. XTL Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -117.29%.

XTL Biopharmaceuticals (NAS:XTLB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

XTL Biopharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	-6.784 * ( 1 - 3.83% )	/	( (8.698	+	0.304)	/ 2 )
=	-6.5241728	/	4.501
=	-144.95 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.55	-	0.719	-	( 1.143	-	max(0, 2.207	-	1.34	+	1.143	))
=	8.698

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.714	-	0.638	-	( 0.259	-	max(0, 0.761	-	0.533	+	0.259	))
=	0.304

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

XTL Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Jun. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.336	/	( ( (0.187 + max(-1.923, 0))	+	(0.167 + max(-0.401, 0)) )	/	2 )
=	-11.336	/	( ( 0.187	+	0.167 )	/	2 )
=	-11.336	/	0.177
=	-6,404.52 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.099	+	0	+	0.047)	-	(0.719	+	0.018	+	1.332)
=	-1.923

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.09	+	0	+	0.184)	-	(0.638	+	0	+	0.037)
=	-0.401

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

XTL Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2025 )
	=	-6.607	/	5.633
	=	-117.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals EBIT Related Terms

XTL Biopharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's EBIT can be seen below:

XTL Biopharmaceuticals EBIT Chart

XTL Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-0.95

-1.03

-1.35

-1.78

-1.13

XTL Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
EBIT	Get a 7-Day Free Trial															-1.23	-0.56	-0.19	-0.94	-5.67

XTLB vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XTL Biopharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's EV-to-EBIT falls into.

Save Embed

24GF Score

XTL Biopharmaceuticals Ltd XTLB

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

XTL Biopharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.61 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-6.61 Mil mean?

XTL Biopharmaceuticals (XTLB) has a EBIT of $-6.61 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on XTL Biopharmaceuticals.

Is XTL Biopharmaceuticals' EBIT too high?

XTL Biopharmaceuticals' current EBIT is $-6.61 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.

How does XTL Biopharmaceuticals' EBIT compare to VRTX and REGN?

XTL Biopharmaceuticals' EBIT of $-6.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on XTL Biopharmaceuticals. XTL Biopharmaceuticals's current EBIT is $-6.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is XTL Biopharmaceuticals stock overvalued right now?

XTL Biopharmaceuticals (XTLB) has a current EBIT of $-6.61 Mil. The current EBIT is $-6.61 Mil. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current EBIT is $-6.61 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies XTAE:PPBT XTAE:CANF XTAE:EVGN XTAE:HDST-M XTAE:BOLT XTAE:BLRX XTAE:CBI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM

Other Exchanges XTLB:Israel HHB0:Germany

Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001

Website https://www.xtlbio.com

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

24GF Score

Get the complete analysis for XTLB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57

Price

View XTLB Analysis

See EBIT data for all stocks →